- Home
- DTIL vs BTAI Comparison
DTIL vs BTAI Comparison
Compare DTIL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | BTAI |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.0M | 49.2M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DTIL | BTAI |
|---|---|---|
| Price | $4.76 | $2.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $47.00 | $32.80 |
| AVG Volume (30 Days) | 256.9K | ★ 635.6K |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $698,000.00 | ★ $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.61 | $1.17 |
| 52 Week High | $8.82 | $9.26 |
Technical Indicators
Market Signals| Indicator | DTIL | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 56.32 |
| Support Level | $4.70 | $1.82 |
| Resistance Level | $5.20 | $2.33 |
| Average True Range (ATR) | 0.38 | 0.17 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 7.02 | 80.41 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.